Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions The Panic-Proof Portfolio (Stockchase Research)
Harmony Biosciences Holdings IncHRMYTOP PICKJul 17, 2025
$35.67
Stock price when the opinion was issued
$34.46
As of Jun 12, 2026. Market Open.
Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly
We reiterate this commercial stage pharma company focusing on neurological treatment as a TOP PICK. It has a long runway of projects in the development pipeline and its histamine focused foundation treatment continues to create positive cash flow and growing cash reserves. We recommend trailing up the stop (from $30) to $33, looking to achieve $50 -- upside potential of 33%. Yield 0%
(Analysts’ price target is $50.55)Pharma & Healthcare
HRMY is a bio-pharma company that has developed cannabis based CBD gels in the US. It is making potentially great strides on developing a treatment for narcolepsy. It trades at 14x earnings, 2.8x book and supports a 24% ROE. Cash reserves are growing, while debt is retired. We recommend setting a stop-loss at $30, looking to achieve $49 -- upside potential of 37%. Yield 0%
(Analysts’ price target is $49.70)